JP2005522490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522490A5 JP2005522490A5 JP2003583400A JP2003583400A JP2005522490A5 JP 2005522490 A5 JP2005522490 A5 JP 2005522490A5 JP 2003583400 A JP2003583400 A JP 2003583400A JP 2003583400 A JP2003583400 A JP 2003583400A JP 2005522490 A5 JP2005522490 A5 JP 2005522490A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- salt
- active ingredient
- pitavastatin
- atorvastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyrazolopyridyl group Chemical group 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 23
- 239000004480 active ingredient Substances 0.000 claims 20
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 12
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 12
- 229960005370 atorvastatin Drugs 0.000 claims 12
- 229960002797 pitavastatin Drugs 0.000 claims 12
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 8
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 6
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 6
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 6
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229960005110 cerivastatin Drugs 0.000 claims 6
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 229960003765 fluvastatin Drugs 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000002883 imidazolyl group Chemical group 0.000 claims 6
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 6
- 125000001041 indolyl group Chemical group 0.000 claims 6
- 229960004844 lovastatin Drugs 0.000 claims 6
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 6
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 6
- 229950009116 mevastatin Drugs 0.000 claims 6
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 6
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000000962 organic group Chemical group 0.000 claims 6
- 229960002965 pravastatin Drugs 0.000 claims 6
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 125000005493 quinolyl group Chemical group 0.000 claims 6
- 229960000672 rosuvastatin Drugs 0.000 claims 6
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 6
- 229960002855 simvastatin Drugs 0.000 claims 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000002596 lactones Chemical class 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 229940122498 Gene expression inhibitor Drugs 0.000 claims 2
- 101150095640 PTX3 gene Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37211402P | 2002-04-15 | 2002-04-15 | |
| US10/196,428 US20030195167A1 (en) | 2002-04-15 | 2002-07-17 | PTX3-gene expression inhibitor |
| PCT/JP2003/004603 WO2003086380A1 (en) | 2002-04-15 | 2003-04-11 | Ptx3 gene expression suppressing method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005522490A JP2005522490A (ja) | 2005-07-28 |
| JP2005522490A5 true JP2005522490A5 (enExample) | 2006-02-09 |
| JP4409295B2 JP4409295B2 (ja) | 2010-02-03 |
Family
ID=28794074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003583400A Expired - Fee Related JP4409295B2 (ja) | 2002-04-15 | 2003-04-11 | Ｐｔｘ３遺伝子発現抑制方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20030195167A1 (enExample) |
| EP (1) | EP1494661B1 (enExample) |
| JP (1) | JP4409295B2 (enExample) |
| AT (1) | ATE445395T1 (enExample) |
| AU (1) | AU2003226456A1 (enExample) |
| DE (1) | DE60329668D1 (enExample) |
| MY (1) | MY137134A (enExample) |
| TW (1) | TWI349547B (enExample) |
| WO (1) | WO2003086380A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060276486A1 (en) * | 2003-04-17 | 2006-12-07 | Kowa Co., Ktd. | Lklf/klf2 gene expression promoter |
| WO2005053683A1 (en) * | 2003-11-26 | 2005-06-16 | Duke University | A method of preventing or treating glaucoma |
| ITRM20030596A1 (it) * | 2003-12-23 | 2005-06-24 | Sigma Tau Ind Farmaceuti | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
| JP4667372B2 (ja) * | 2004-02-25 | 2011-04-13 | 株式会社ペルセウスプロテオミクス | 血管障害の程度の判定方法 |
| AU2005237543B2 (en) * | 2004-04-26 | 2011-02-10 | Alcon, Inc. | Statins for the treatment of ocular hypertension and glaucoma |
| WO2008001499A1 (en) * | 2006-06-29 | 2008-01-03 | Kowa Co., Ltd. | Prophylactic and/or therapeutic agent for rheumatoid arthritis |
| CN106950366B (zh) * | 2017-02-15 | 2019-03-22 | 中国医学科学院北京协和医院 | 一种acpa阴性的ra诊断标志物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244916A (en) * | 1992-01-31 | 1993-09-14 | The Scripps Research Institute | Inhibition of respiratory burst using posttranslational modification inhibitors |
| WO1999026657A1 (en) * | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| CA2365869A1 (en) * | 1999-03-08 | 2000-09-14 | Richard D. Tillyer | Crystalline hydrated dihydroxy open-acid simvastatin calcium salt |
| US6403637B1 (en) * | 1999-08-09 | 2002-06-11 | Univ Saint Louis | Methods of modulating matrix metalloproteinase activity and uses thereof |
| AU2001232245A1 (en) * | 2000-02-10 | 2001-08-20 | Takeda Chemical Industries Ltd. | Tnf- alpha inhibitors |
| US20020156122A1 (en) * | 2000-09-19 | 2002-10-24 | Novlmmune S.A. | Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| US20020159974A1 (en) * | 2000-09-19 | 2002-10-31 | Francois Mach | Treatment of multiple sclerosis with statins (HMG-CoA reductase inhibitors) |
-
2002
- 2002-07-17 US US10/196,428 patent/US20030195167A1/en not_active Abandoned
-
2003
- 2003-04-08 MY MYPI20031287A patent/MY137134A/en unknown
- 2003-04-11 TW TW092108385A patent/TWI349547B/zh not_active IP Right Cessation
- 2003-04-11 AT AT03746454T patent/ATE445395T1/de not_active IP Right Cessation
- 2003-04-11 DE DE60329668T patent/DE60329668D1/de not_active Expired - Lifetime
- 2003-04-11 WO PCT/JP2003/004603 patent/WO2003086380A1/en not_active Ceased
- 2003-04-11 JP JP2003583400A patent/JP4409295B2/ja not_active Expired - Fee Related
- 2003-04-11 AU AU2003226456A patent/AU2003226456A1/en not_active Abandoned
- 2003-04-11 EP EP03746454A patent/EP1494661B1/en not_active Expired - Lifetime
-
2007
- 2007-03-30 US US11/694,288 patent/US20080161348A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2445312C2 (ru) | ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR | |
| CA2429979A1 (en) | Treatment of statin side effects | |
| JP2015528471A5 (enExample) | ||
| TNSN06439A1 (fr) | Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique | |
| WO2012031445A1 (en) | Processes for preparing piperazinium salts of kmup and use thereof | |
| RU2002100058A (ru) | Кристаллические производные 1-метилкарбапенема | |
| JP2005522490A5 (enExample) | ||
| CA2335366A1 (en) | Compositions and methods for treating elevated blood cholesterol | |
| JP2015505550A5 (enExample) | ||
| US20080161348A1 (en) | Ptx3-gene expression inhibitor | |
| KR20110091600A (ko) | 고안압증과 녹내장의 치료용 스타틴 | |
| RU2003113328A (ru) | Профилактическое и терапевтическое средство для лечения осложнений, связанных с диабетом | |
| JP2012520279A (ja) | ロスバスタチンおよびアトルバスタチン誘導体 | |
| KR20130137623A (ko) | 림프 부종 예방 치료제 | |
| RU98106104A (ru) | Производные пиримидина | |
| JP2005525391A5 (enExample) | ||
| JP2007534731A5 (enExample) | ||
| RU2014145102A (ru) | Комбинация | |
| CA2492781A1 (en) | Medicinal composition for mitigating blood lipid or lowering blood homocystein | |
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| CA2529367A1 (en) | Preventing atrial fibrillation (af) with the use of statin drugs | |
| WO2005058310A3 (en) | Use of stating for the treatment of metabolic syndrome | |
| US20080070938A1 (en) | Medicinal composition for mitigating blood lipid or lowering blood homocysteine | |
| RU2007148908A (ru) | Составы для снижения риска возникновения вызванной лекарственными средствами аритмии | |
| JP2005501846A (ja) | 新規組合せ製品 |